Clinical trial
Extension Study of Protocol CT-EV-31s to Examine the Long-Term Immunogenicity After Receiving Inactivated EV71 Enterovirus Vaccine (Envacgen®) in Children
NCT07568522 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Extension Study of Protocol CT-EV-31s to Examine the Long-Term Immunogenicity After Receiving Inactivated EV71 Enterovirus Vaccine (Envacgen®) in Children
- Lead sponsor
- Medigen Vaccine Biologics Corp.
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 24, 2025
- Completion date
- June 26, 2026
- Enrollment
- 220 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
enterovirus 71 human